Coherus BioSciences, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Coherus BioSciences, Inc.
The 10 US Biosimilar Launches That Could Drive Big Savings By 2027
Biosimilar versions of drugs like Humira, Eylea and Keytruda are among the products that could generate cumulative sales of $129bn over the next five years, according to IQVIA.
Coherus Pulls A Rabbit Out Of The Hat With Inventive Pegfilgrastim Form
Coherus’ year-end financial results included a surprise – a newly approved formulation of pegfilgrastim.
Coherus Queries Higher Dose Aflibercept Amid Biosimilar Eylea Deal
Coherus BioSciences is feeling bullish about its potential in the biosimilar ophthalmology space after agreeing to bring on board a biosimilar Eylea (aflibercept) candidate, with an eye on launching potentially in 2025.
Coherus Files On-Body Pegfilgrastim, Says ‘People Talk’ On Potential Rivals
Having previously underlined that it would not tell the market the exact moment it filed its proposed biosimilar pegfilgrastim on-body injector device, Coherus BioSciences has now confirmed a filing was completed late last year.
- Generic Drugs
- Large Molecule
- Other Names / Subsidiaries
- InteKrin Therapeutics, Inc.
- Coherus Intermediate Corp
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.